CD8A and neoplasm: The distribution of the four tumor immune microenvironment types was 12.96% (type I, CD8+PD-L1+), 42.73% (type II, CD8−PD-L1−), 28.02% (type III, CD8−PD-L1+) and 16.28% (type IV, CD8+PD-L1−) in the complete cohort.